Two-in-One Polymeric NO-Donor Prodrugs Mediate Precision and Synergistic Prostate Cancer Treatment
Lists
Only you see this
Abstract
Chemotherapy predominates in clinical treatment of prostate cancer (PCa), while irreversible resistance to chemotherapeutics and severe side effects hinder the therapeutic efficacy, especially in castration-resistant PCa (CRPC). Herein, a bombesin (BBN)-decorated two-in-one prodrug (T-NO/E<sub>2</sub>-PMs) incorporating a polymeric nitric oxide (NO) donor and acetal-linked 17β-estradiol (E<sub>2</sub>) in one backbone is developed, aiming to inhibit androgen receptor (AR) expression, reprogram the tumor microenvironment of CRPC, and enhance estradiol-mediated hypoxic CRPC therapy. Following efficient internalization mediated by BBN, T-NO/E<sub>2</sub>-PMs releases estradiol and NO in response to the unique intracellular environments. Both <i>in vitro</i> and <i>in vivo</i> studies demonstrate that the T-NO/E<sub>2</sub>-PMs nano-prodrug along with NO release potently downregulates AR levels to reverse CRPC and further enhances the chemo-sensitization of estradiol to PCa PC-3 cell apoptosis and the inhibition of metastasis. Collectively, this two-in-one nano-prodrug strategy offers a promising platform for construction of advanced nanomedicine to boost the therapeutic efficacy.
BibTeX
@inproceedings{zhao2023two,
author = {Bing Zhao and Yuqing Wan and Xiang Zhou and Junmei Zhang and Jiaxin Chen and Jiachen Yang and Yunzhu Liu and Wei Chen and Yinan Zhong and Hongliang Qian},
title = {{Two-in-One Polymeric NO-Donor Prodrugs Mediate Precision and Synergistic Prostate Cancer Treatment}},
booktitle = {ACS},
year = {2023},
doi = {10.1021/acsami.3c04167},
}Loading related content...